Cargando…
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Targeted therapies require information on specific defective signaling pathways or mutations. Advances in genomic technologies and cell biology have led to identification of new therapeutic targets associated with signal-transduction pathways. Survival times of patients with colorectal cancer (CRC)...
Autores principales: | Seow, Heng Fong, Yip, Wai Kien, Fifis, Theodora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821380/ https://www.ncbi.nlm.nih.gov/pubmed/27099521 http://dx.doi.org/10.2147/OTT.S95101 |
Ejemplares similares
-
The current status of immunobased therapies for metastatic renal-cell carcinoma
por: Sathianathen, Niranjan J, et al.
Publicado: (2017) -
Epstein-Barr virus latent membrane protein-1 (LMP-1) 30-bp deletion and Xho I-loss is associated with type III nasopharyngeal carcinoma in Malaysia
por: See, Hui Shien, et al.
Publicado: (2008) -
Isolation and Identification of Long Non-Coding RNAs in Exosomes Derived from the Serum of Colorectal Carcinoma Patients
por: Ng, Chin Tat, et al.
Publicado: (2021) -
SAR131675, a VEGRF3 Inhibitor, Modulates the Immune Response and Reduces the Growth of Colorectal Cancer Liver Metastasis
por: Walsh, Katrina A., et al.
Publicado: (2022) -
The kallikrein-Kinin system modulates the progression of colorectal liver metastases in a mouse model
por: da Costa, Patricia Luiza Nunes, et al.
Publicado: (2018)